Clinical Investigation of Healon EndoCoat Ophthalmic Viscosurgical Device (OVD)
Study Details
Study Description
Brief Summary
Prospective, multicenter, paired-eye, randomized, subject/evaluator-masked clinical investigation of the experimental EndoCoat OVD versus the control EndoCoat OVD.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Investigational Healon EndoCoat Eligible subjects to be randomly assigned to receive investigational Healon EndoCoat in one eye and control Healon EndoCoat in fellow eye. |
Device: Investigational Healon Endocoat
Ophthalmic Viscoelastic device
Device: Control Healon EndoCoat
Ophthalmic Viscoelastic device
|
| Active Comparator: Control Healon EndoCoat Eligible subjects to be randomly assigned to receive investigational Healon EndoCoat in one eye and control Healon EndoCoat in fellow eye. |
Device: Investigational Healon Endocoat
Ophthalmic Viscoelastic device
Device: Control Healon EndoCoat
Ophthalmic Viscoelastic device
|
Outcome Measures
Primary Outcome Measures
- CUMULATIVE RATE OF INTRAOCULAR PRESSURE (IOP) SPIKES 30 MMHG OR GREATER [up to 3-month follow-up]
The cumulative count and proportion of eyes with an IOP spike at 3 months will be reported by OVD. Any IOP measurements of 30 mmHg or greater are to be considered a "spike".
- MEAN PERCENT ENDOTHELIAL CELL COUNT (ECC) CHANGE PREOPERATIVELY VS. POSTOPERATIVELY [up to 3-month follow-up]
The percent change in ECC from preoperative to 3 months postoperative will be reported by descriptive statistics by OVD.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Minimum 22 years of age
-
Cataracts for which extraction and posterior chamber IOL implantation have been planned in both eyes
-
Potential for postoperative best corrected distance visual acuity (BCDVA) of 20/40 Snellen or better
-
Clear intraocular media, other than cataract
-
Availability, willingness and sufficient cognitive awareness to comply with examination procedures
-
Signed informed consent and HIPAA authorization
Exclusion Criteria:
-
Pupil abnormalities (non-reactive, fixed pupils, or abnormally shaped pupils)
-
Recent ocular trauma or ocular surgery that is not resolved/stable or may affect clinical outcomes or increase risk to the subject
-
Prior corneal refractive (LASIK, LASEK, RK, PRK, etc.) or intraocular surgery
-
Subjects with diagnosed degenerative visual disorders (e.g., macular degeneration or other retinal disorders) that are predicted to cause visual acuity losses to a level worse than 20/40 Snellen during the study.
-
Prior, current, or anticipated use during the course of the 3-month study of tamsulosin or silodosin (e.g., Flomax, Flomaxtra, Rapaflo) that may, in the opinion of the investigator, confound the outcome or increase the risk to the subject (e.g., poor dilation or a lack of adequate iris structure to perform standard cataract surgery)
-
Conditions associated with increased risk of zonular rupture, including capsular or zonular abnormalities that may lead to IOL decentration or tilt, such as pseudoexfoliation, trauma, or posterior capsule defects
-
Use of systemic or ocular medications that may affect vision or IOP
-
Corneal abnormalities such as stromal, epithelial or endothelial dystrophies that are predicted to cause visual acuity losses to a level worse than 20/40 Snellen during the study, or in the opinion of the investigator, may confound the outcome(s) of the study
-
Poorly-controlled diabetes
-
Acute, chronic, or uncontrolled systemic or ocular disease or illness that, in the opinion of the investigator, would increase the operative risk or confound the outcome(s) of the study (e.g., immunocompromised, connective tissue disease, suspected glaucoma, glaucomatous changes in the fundus or visual field, ocular inflammation, etc.).
-
Known steroid responder
-
Ocular hypertension of ≥ 20 mmHg, medically-controlled ocular hypertension (regardless of IOP value), or glaucomatous changes in the optic nerve
-
Endothelial cell count (ECC) lower than 1800 cells/mm2 preoperatively (based on the average of the three cell counts as taken by the Konan Specular Microscope)
-
Known ocular disease or pathology that may affect visual acuity or that may be expected to require retinal laser treatment or other surgical intervention during the course of the study (macular degeneration, cystoid macular edema, diabetic retinopathy, etc.)
-
Patient is pregnant, plans to become pregnant, is lactating or has another condition associated with the fluctuation of hormones that could lead to refractive changes
-
Concurrent participation or participation within 60 days prior to preoperative visit in any other clinical trial
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Empire Eye & Laser Center | Bakersfield | California | United States | 93309 |
| 2 | Southern California Eye Physicians and Associates | Long Beach | California | United States | 90805 |
| 3 | Berkeley Eye Institute, P.A. | Houston | Texas | United States | 77027 |
| 4 | Focal Point Vision | San Antonio | Texas | United States | 78209 |
| 5 | Parkhurst NuVision | San Antonio | Texas | United States | 78229 |
Sponsors and Collaborators
- Johnson & Johnson Surgical Vision, Inc.
Investigators
- Study Director: Johnson & Johnson Surgical Vision, Inc. Clinical Trial, Johnson & Johnson Surgical Vision, Inc.
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- VSCO-110-LOKE